NEW YORK, July 29, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Indiana on behalf of investors who purchased Endocyte, Inc. ("Endocyte" or the "Company") (Nasdaq:ECYT) common stock between March 21, 2014 and May 2, 2014.
Click here to learn about the case: http://docs.wongesq.com/ECYT-Info-Request-Form-325. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued misleading statements regarding the efficacy of the Company's experimental drug VYNFINIT, and misrepresented and/or failed to disclose material information regarding the Company's business and financial prospects. In particular it is alleged that Endocyte misrepresented the nature of positive statements made about the drug in a March 21 press release, capitalizing on the resulting stock price increase to issue a public offering and sell shares at an inflated price.
If you suffered a loss in Endocyte you have until August 25, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ECYT-Info-Request-Form-325.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
